CuraGen to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and CR011-vcMMAE Phase II Trial Results on Novemb... ( BRANFORD Conn. Oct. 29 /- CuraGen...)

HOME >> MEDICINE >> TECHNOLOGY

CuraGen to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and CR011-vcMMAE Phase II Trial Results on November 3, 2008

Date:10/29/2008

BRANFORD, Conn., Oct. 29 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN), a clinical-stage biopharmaceutical company focused on oncology, announced today that Company executives will be holding a conference call and webcast at 11:00 a.m. ET on Monday, November 3, 2008 following the release of third quarter 2008 financial results and to review preliminary data from CuraGen's Phase II clinical trial evaluating CR011-vcMMAE for the treatment of advanced melanoma.

Data from CuraGen's Phase II trial of CR011-vcMMAE will be presented during an oral session at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer (iSBTc), being held October 31 - November 2, 2008, in San Diego, CA. The results will be presented on Saturday, November 1, 2008, at 3:15 p.m. Pacific time in the Tumor Targeting Monoclonal Antibodies session.

Press releases detailing the financial results and the Phase II data on CR011-vcMMAE will be issued prior to market open on Monday, November 3, 2008.

Conference Call and Webcast Details

Date: Monday, November 3, 2008

Time: 11:00 a.m. ET

Dial-in: 877-272-5391 (domestic)

706-758-4315 (international)

Passcode: 71190212

Webcast: Accessible at http://www.curagen.com

A replay of the conference call and webcast will be available beginning at 2:00 p.m. ET on Monday, November 3, 2008 through Wednesday, December 3, 2008 by dialing 800-642-1687 (domestic) or 706-645-9291 (international). The passcode for the replay is 71190212. An archive of the webcast will also be available for 30 days at http://www.curagen.co
'/>"/>

0

GOOD

Page: 1 2
Related medicine technology :

1. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
2. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
3. CuraGen Announces Top-Line Phase II Results on Velafermin
4. CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma
5. CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference
6. CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting
7. CuraGen Advances CR011-vcMMAE into Phase II
8. CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
9. CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Melanoma
10. CuraGen Announces Initiation of Phase II Trial of CR011-vcMMAE in Patients with Advanced Breast Cancer
11. CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE

Post Your Comments:

CuraGen to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and CR011-vcMMAE Phase II Trial Results on Novemb...( BRANFORD Conn. Oct. 29 /- CuraGen...),Health